US20190117721A1 - Health functional food for inhibiting rise of blood glucose containing coffee and tagatose - Google Patents

Health functional food for inhibiting rise of blood glucose containing coffee and tagatose Download PDF

Info

Publication number
US20190117721A1
US20190117721A1 US16/096,949 US201716096949A US2019117721A1 US 20190117721 A1 US20190117721 A1 US 20190117721A1 US 201716096949 A US201716096949 A US 201716096949A US 2019117721 A1 US2019117721 A1 US 2019117721A1
Authority
US
United States
Prior art keywords
blood glucose
health functional
functional food
tagatose
coffee
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/096,949
Other languages
English (en)
Inventor
Byung Gyu Park
Young Mi Lee
Seong Bo Kim
Seung Won Park
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CJ CheilJedang Corp
Original Assignee
CJ CheilJedang Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CJ CheilJedang Corp filed Critical CJ CheilJedang Corp
Assigned to CJ CHEILJEDANG CORPORATION reassignment CJ CHEILJEDANG CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KIM, SEONG BO, LEE, YOUNG MI, PARK, BYUNG GYU, PARK, SEUNG WON
Publication of US20190117721A1 publication Critical patent/US20190117721A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/74—Rubiaceae (Madder family)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
    • A23F5/00—Coffee; Coffee substitutes; Preparations thereof
    • A23F5/24—Extraction of coffee; Coffee extracts; Making instant coffee
    • A23F5/36—Further treatment of dried coffee extract; Preparations produced thereby, e.g. instant coffee
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
    • A23F5/00—Coffee; Coffee substitutes; Preparations thereof
    • A23F5/24—Extraction of coffee; Coffee extracts; Making instant coffee
    • A23F5/36—Further treatment of dried coffee extract; Preparations produced thereby, e.g. instant coffee
    • A23F5/40—Further treatment of dried coffee extract; Preparations produced thereby, e.g. instant coffee using organic additives, e.g. milk, sugar
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
    • A23F5/00—Coffee; Coffee substitutes; Preparations thereof
    • A23F5/24—Extraction of coffee; Coffee extracts; Making instant coffee
    • A23F5/36—Further treatment of dried coffee extract; Preparations produced thereby, e.g. instant coffee
    • A23F5/42—Further treatment of dried coffee extract; Preparations produced thereby, e.g. instant coffee using inorganic additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A23L2/60—Sweeteners
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/74—Rubiaceae (Madder family)
    • A61K36/742—Coffea, e.g. coffee
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/20—Natural extracts
    • A23V2250/21—Plant extracts
    • A23V2250/2108—Caffeine, coffee extract
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/60—Sugars, e.g. mono-, di-, tri-, tetra-saccharides
    • A23V2250/634—Tagatose

Definitions

  • the present invention relates to a health functional food for inhibiting a rise in blood glucose, which includes coffee and tagatose.
  • glucose is a raw material important as an energy source for red blood cells and brain cells.
  • Glucose in blood is referred to as blood glucose, and energy may be supplied to our bodies when the blood glucose always has to be maintained at a constant level.
  • a constant level of blood glucose is maintained by various hormones and enzymes.
  • Insulin and glucagon are most representative of the hormones and enzymes. In this case, when ones do not eat food or require a large amount of energy, glucagon is secreted to help to release glucose, which has been stored in the liver, into blood so that the blood glucose can be maintained at a normal level.
  • insulin is secreted from the pancreas.
  • insulin sends signals to store glucose in the liver, and promotes the use of glucose in cells of respective tissues to control a blood glucose level to a normal level.
  • blood glucose In a normal state, blood glucose temporarily rises after meal, but returns to a normal level in response to insulin. However, when insulin is not normally secreted from the pancreas or insulin is secreted but does not function normally, the blood glucose does not return to a normal level after meal. That is, the bodies do not use glucose as energy source, thereby making impossible to excrete the glucose. When a level of blood glucose higher than a normal level lasts, it may interfere with regulatory components circulated through blood, reduce the functions of red and white blood cells, or put the pressure on the kidney, thereby negatively affecting our bodies.
  • tagatose is a naturally existing rare sucrose that is included as a trace element in foods such as dairy products, fruits, and the like, and has been registered as the FDA GRAS and EU Novel Food and approved to be safe by the Korea Food & Drug Administration (KFDA).
  • the KFDA has approved tagatose as a raw material which help to inhibit a rise in blood glucose after meal
  • tagatose functions to inhibit a rise in blood glucose when taken with caffeine-containing coffee known to promote a rise in blood glucose after meal and taken with coffee (for example, a coffee mix) with a coffee creamer (glycemic index: 24) having a glycemic index (GI) higher than tagatose.
  • the patent (Registered Patent No. 10-1366404; Korean Patent Publication No. 2011-0047976) by the present inventors discloses a low-calorie coffee-mix composition in which tagatose is used instead of sucrose to make natural sweet tastes. However, there is no report on the coffee mix that functions to inhibit a rise in blood glucose.
  • the present inventors have ardently conducted research to confirm whether a tagatose coffee mix has an effect of inhibiting a rise in blood glucose, and found that the tagatose coffee mix has an excellent effect of inhibiting a rise in blood glucose, compared to the control and a sucrose coffee mix. Therefore, the present invention has been completed based on the facts.
  • a health functional food for inhibiting a rise in blood glucose, which includes coffee and tagatose.
  • a health functional food for inhibiting a rise in blood glucose which includes coffee and tagatose.
  • coffee used herein refers to a powder of coffee obtained by roasting and grinding the fruit of a coffee tree, and includes a coffee been powder and instant black coffee, which are sold and distributed in various forms on the market, but the present invention is not limited thereto.
  • the coffee of the present invention may contain caffeine.
  • tagatose refers to an isomer of galactose under the IUPAC name of (3S,4S,5R)-1,3,4,5,6-pentahydroxy-hexan-2-one.
  • the tagatose of the present invention may be directly extracted from natural substances, and may be prepared using a chemical synthesis or biological method (for example, fermentation using microorganisms or enzymes), but the present invention is not limited thereto.
  • the tagatose of the present invention may be included at a dose of 6 g/day to 10 g/day. Particularly, the tagatose of the present invention may be included at a dose of 6 g/day to 7.5 g/day, 6 g/day to 7 g/day, 6 g/day to 6.5 g/day, or 6 g/day.
  • the tagatose of the present invention may be provided in a crystalline form or in the form of a syrup containing tagatose.
  • the tagatose-containing syrup may contain a varying amount of tagatose, based on the dried solid content (DS).
  • the tagatose of the present invention may be included at a tagatose content of 95% or more, and more particularly at a tagatose content of 96% or more, 97% or more, 98% or more, 99% or more, 99.5% or more, 99.5% to 99.9%, 99.5% to 99.8%, 99.5% to 99.7%, 99.5% to 99.6%, or 99.5%, based on the weight of dries solids.
  • the tagatose of the present invention may be in a crystalline form.
  • the tagatose of the present invention may have any characteristics such as crystal morphology, particle size, crystal shape, or other physical characteristics in terms of the health functional food (for example, a health functional coffee mix) of the present invention.
  • the health functional food of the present invention may further include a milk protein.
  • milk protein used herein refers to a protein or derivatives thereof included in milk, and may be particularly selected from the group consisting of casein, sodium caseinate, a milk protein isolate, and a milk protein concentrate. More particularly, the milk protein of the present invention may be selected from the group consisting of casein, sodium caseinate, and a milk protein concentrate.
  • the health functional food of the present invention may further include starch syrup.
  • starch syrup used herein refers to a starch hydrolysate.
  • the starch syrup of the present invention may include maltose. More particularly, the starch syrup may include maltose and glucose and/or dextrin.
  • the inhibition of the rise in blood glucose may include a decrease in a blood glucose level by 3% to 20%, particularly by 3% to 15%, 3% to 10%, 3% to 7.6%, 3% to 6.35%, 5% to 20%, 5% to 15%, 5% to 10%, 5% to 7.6%, 5% to 6.35%, 6.35% to 7.6%, 6.35%, or 7.6% within 30 minutes to 45 minutes after the intake of the health functional food of the present invention relative to a blood glucose level of the control who does not eat the health functional food of the present invention.
  • the inhibition of the rise in blood glucose may include a decrease in an area under the blood glucose response curve (AUC) by 2% to 10%, particularly by 2% to 7%, 2% to 5%, 2% to 3.8%, 3% to 10%, 3% to 7%, 3% to 5%, 3% to 3.8%, 3.8% to 10%, 3.8% to 7%, 3.8% to 5%, or 3.8% within 0 minutes to 120 minutes after the intake of the health functional food of the present invention relative to an area under the blood glucose response curve of the control who does not eat the health functional food of the present invention.
  • AUC blood glucose response curve
  • the inhibition of the rise in blood glucose may include a decrease in a blood glucose level by 3% to 20%, particularly by 3% to 15%, 3% to 10%, 3% to 8%, 3% to 7.7%, 5% to 20%, 5% to 15%, 5% to 10%, 5% to 8%, 5% to 7.7%, 7% to 20%, 7% to 15%, 7% to 10%, 7% to 8%, 7% to 7.7%, or 7.7% within 30 minutes after the intake of the health functional food of the present invention relative to a blood glucose level of the control who eats tagatose instead of sucrose in the health functional food of the present invention.
  • the inhibition of the rise in blood glucose may include a decrease in a blood glucose level by 3% to 20%, particularly by 3% to 15%, 3% to 13%, 3% to 12.7%, 3% to 11%, 3% to 10.8%, 5% to 20%, 5% to 15%, 5% to 13%, 5% to 12.7%, 5% to 11%, 5% to 10.8%, 8% to 20%, 8% to 15%, 8% to 13%, 8% to 12.7%, 8% to 11%, 8% to 10.8%, 10% to 20%, 10% to 15%, 10% to 13%, 10% to 12.7%, 10% to 11%, 10% to 10.8%, 10.8% to 20%, 10.8% to 15%, 10.8% to 13%, 10.8% to 12.7%, 12.7% to 20%, 12.7% to 15%, 12.7% to 13%, 10.8%, or 12.7% within 15 minutes to 30 minutes after the intake of the health functional food of the present invention relative to a blood glucose level of the control who eats sucrose instead of tagatose in the health functional food of the present invention.
  • the inhibition of the rise in blood glucose may include a decrease in an area under the blood glucose response curve by 2% to 10%, particularly by 2% to 8%, 2% to 6%, 2% to 5.49%, 3% to 10%, 3% to 8%, 3% to 6%, 3% to 5.49%, 5% to 10%, 5% to 8%, 5% to 6%, 5% to 5.49%, 5.49% to 10%, 5.49% to 8%, 5.49% to 6%, or 5.49% within 0 minutes to 90 minutes after the intake of the health functional food of the present invention relative to an area under the blood glucose response curve of the control who does not eat the health functional food of the present invention.
  • the food of the present invention may be used without limitation as long as it contains coffee and tagatose.
  • Examples of the food of the present invention include bread, cake, chocolate, candies, confectionery (cookies, crackers, and the like), dairy products including ice creams, drinks and alcoholic beverages, and the like, the present invention is not limited thereto.
  • the food of the present invention may be a coffee mix.
  • the term “coffee mix” used herein refers to a food formulation which is packaged to include coffee as well as other additives (for example, a sweetener and/or a coffee creamer).
  • the term “coffee creamer” used herein refers to an additive which serves to make coffee including a milk protein soft and rich in flavors, and may particularly further include starch syrup, and more particularly a vegetable oil, an emulsifying agent, a stabilizing agent and/or a buffer, all of which may be used for foods.
  • both of the health functional food of the present invention and the inhibition of the rise in blood glucose are applied as described above.
  • administration refers to an introduction of a certain material to a subject of interest in any proper manner.
  • the certain material may be administered through any general route of administration through which a composition of the present invention may reach an in vivo target.
  • the routes of administration of the health functional food of the present invention are not particularly limited, but the health functional food of the present invention may be administered orally or parenterally. Particularly, the health functional food of the present invention may be administered orally.
  • the administration of the present invention may be performed so that the tagatose is included at a dose of 6 g/day to 10 g/day, 6 g/day to 7.5 g/day, 6 g/day to 7 g/day, 6 g/day to 6.5 g/day, or 6 g/day, based on the total weight of the health functional food of the present invention.
  • a rise in blood glucose is inhibited even when tagatose is taken with caffeine-containing coffee and/or a coffee creamer having a high glycemic index (GI).
  • GI glycemic index
  • FIG. 1 is a graph illustrating a change in blood glucose according to the intake of a coffee mix including tagatose, erythritol or sucrose according to one exemplary embodiment of the present invention.
  • FIG. 2 is a graph illustrating a change in an area under the blood glucose response curve (AUC) according to the intake of a coffee mix including tagatose, erythritol or sucrose according to one exemplary embodiment of the present invention.
  • AUC blood glucose response curve
  • FIG. 3 2 is a graph illustrating a change in blood glucose according to the intake of a coffee mix including tagatose or sucrose along with coffee and a coffee creamer according to one exemplary embodiment of the present invention.
  • FIG. 4 is a graph illustrating a change in an area under the blood glucose response curve according to the intake of a coffee mix including tagatose or sucrose along with coffee and a coffee creamer according to one exemplary embodiment of the present invention.
  • FIG. 5 is a graph illustrating a change in blood glucose according to milk proteins included in the coffee creamer according to one exemplary embodiment of the present invention.
  • FIG. 6 is a graph illustrating a change in in an area under the blood glucose response curve according to milk proteins included in the coffee creamer according to one exemplary embodiment of the present invention.
  • Coffee mixes were prepared as listed in the following Table 1.
  • instant coffee (Maxim Mocha Gold Original, Dongsuh Food Co. Ltd.) was used as coffee in comparative examples and examples, and 6 g of tagatose (crystalline tagatose containing 98.5% tagatose, CJ CheilJedang Corp.) (Example 1), and 5 g of sucrose (white sucrose, CJ CheilJedang Corp.) (Comparative Example 1) and 8.4 g of erythritol (Zibo Zhongshi Green Biotech Co., Ltd) (Comparative Example 2) whose contents were adjusted to exhibit a degree of sweetness similar to that of the tagatose were used as a sweetener added to the coffee mixes in Comparative Examples 1 and 2 and Example 1.
  • the erythritol was used as the placebo in Comparative Example 2 in which erythritol was added as a sweetening ingredient (0 Kcal, GI: 0) which had no effects on blood glucose.
  • Coffee mixes of Examples 2 and 3 were prepared by further adding 6 g of coffee creamer 1 (a starch syrup including hydrogenated vegetable fats, natural casein, dibasic potassium phosphate, and an emulsifying agent; ‘Prima’ from Dongsuh Food Co. Ltd.) and 6 g of coffee creamer 2 (a starch syrup including hydrogenated vegetable fats, non-fat milk, dibasic potassium phosphate, and a powder of milk protein concentrate; Namyang French Cafe Mix Creamer) to the coffee mix of Example 1, respectively.
  • a coffee mix of Comparative Example 3 was prepared by replacing sucrose for only tagatose of Example 3.
  • Example material sweetness 1 (g) 2 (g) 1 (g) 2 (g) 3 (g) 3 (g) Sucrose 1 5 — — — — 6 Erythritol 0.85 — 8.4 — — — — Tagatose 0.6 — — 6 6 6 — Coffee — 1.6 1.6 1.6 1.6 1.6 Coffee — — — 6 — — creamer 1 Coffee — — — — — 6 6 creamer 2
  • Example 1 To measure changes in blood glucose after the intake of the coffee mixes of Example 1 and Comparative Examples 1 and 2 prepared in Preparative Example 1, the following experiment was performed on 21 healthy persons (12 males and 9 females), with an average age of 32.4 ⁇ 5.5 years (between 25 and 42 years), who had a fasting blood sucrose level of 100 mg/dL or less.
  • the subjects who had fasted since 10 p.m. the night before were randomly fed with muffin (a total of 326 kcal, including 19 g of sucrose) and the coffee mixes of Example 1 and Comparative Examples 1 and 2 (to perform randomization, double-blind, and cross-over tests).
  • the tagatose-containing coffee mix of Example 1 exhibited a significant decrease in blood glucose by 7.6% within 30 minutes after meal and a decrease in blood glucose by 6.35% within 45 minutes after meal, and also exhibited a significant decrease in an area under the blood glucose response curve (AUC) by 3.8% within 120 minutes after meal, compared to the placebo of Comparative Example 2. Also, it was revealed that the tagatose-containing coffee mix of Example 1 exhibited a significant decrease (7.7%) within 30 minutes after meal, compared to the sucrose-containing coffee mix of Comparative Example 1 ( FIGS. 1 and 2 ).
  • Example 3 the subjects who had fasted since 10 p.m. the night before were randomly fed with the coffee mixes of Example 3 and Comparative Example 3 prepared in Preparative Example 1 (to perform randomization, double-blind, and cross-over tests).
  • the rise in blood glucose after meal was significantly inhibited when the caffeine-containing coffee and the tagatose-containing coffee mix including a coffee creamer having a high GI were taken at a dose of 6 g/day or more, compared to the existing commercial product, that is, a coffee mix containing sucrose and a coffee creamer.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Nutrition Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Tea And Coffee (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dairy Products (AREA)
US16/096,949 2016-05-04 2017-05-04 Health functional food for inhibiting rise of blood glucose containing coffee and tagatose Abandoned US20190117721A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20160055307 2016-05-04
KR10-2016-0055307 2016-05-04
PCT/KR2017/004717 WO2017192021A1 (ko) 2016-05-04 2017-05-04 커피 및 타가토스를 함유하는 혈당 상승 억제용 건강기능성 식품

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2017/004717 A-371-Of-International WO2017192021A1 (ko) 2016-05-04 2017-05-04 커피 및 타가토스를 함유하는 혈당 상승 억제용 건강기능성 식품

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/931,662 Division US11406680B2 (en) 2016-05-04 2020-07-17 Health functional food for inhibiting rise of blood glucose containing coffee and tagatose

Publications (1)

Publication Number Publication Date
US20190117721A1 true US20190117721A1 (en) 2019-04-25

Family

ID=60202980

Family Applications (2)

Application Number Title Priority Date Filing Date
US16/096,949 Abandoned US20190117721A1 (en) 2016-05-04 2017-05-04 Health functional food for inhibiting rise of blood glucose containing coffee and tagatose
US16/931,662 Active US11406680B2 (en) 2016-05-04 2020-07-17 Health functional food for inhibiting rise of blood glucose containing coffee and tagatose

Family Applications After (1)

Application Number Title Priority Date Filing Date
US16/931,662 Active US11406680B2 (en) 2016-05-04 2020-07-17 Health functional food for inhibiting rise of blood glucose containing coffee and tagatose

Country Status (10)

Country Link
US (2) US20190117721A1 (da)
EP (1) EP3453262B1 (da)
JP (1) JP6849171B2 (da)
KR (1) KR20170125298A (da)
CN (1) CN109152382A (da)
DK (1) DK3453262T3 (da)
ES (1) ES2946171T3 (da)
MY (1) MY200199A (da)
PL (1) PL3453262T3 (da)
WO (1) WO2017192021A1 (da)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240138456A1 (en) * 2021-03-05 2024-05-02 Asahi Group Foods, Ltd. Composition containing decomposition product of yeast cell wall, method for producing same, and use thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010002269A1 (en) 1997-05-06 2001-05-31 Zhao Iris Ginron Multi-phase food & beverage
ES2196753T3 (es) 1998-01-05 2003-12-16 Arla Foods Amba Uso de d-tagatosa comosinergizador e intensificador del sabor.
KR100720055B1 (ko) 2004-07-15 2007-05-18 한국생명공학연구원 육탄당 모노인산을 포함하는 혈당강하용 조성물
KR100779160B1 (ko) * 2005-12-29 2007-11-28 주식회사 삼양제넥스 타가토스를 함유하는 저혈당지수 혼합 조성물
JP4771882B2 (ja) * 2006-07-21 2011-09-14 味の素ゼネラルフーヅ株式会社 糖尿病または糖尿病性合併症の治療、予防、または改善作用を有する組成物およびこれを含有する飲料
JP5094150B2 (ja) * 2007-02-08 2012-12-12 三和澱粉工業株式会社 血糖値上昇抑制剤
KR100982012B1 (ko) * 2008-02-12 2010-09-13 주식회사 한국발보린 커피믹스 및 그 제조방법
JP5006248B2 (ja) * 2008-04-23 2012-08-22 太陽化学株式会社 乳成分入りコーヒー飲料
JP5749880B2 (ja) * 2008-05-27 2015-07-15 松谷化学工業株式会社 Ｄ−タガトースを有効成分とする体脂肪蓄積改善剤およびメタボリックシンドローム改善剤
KR101366404B1 (ko) * 2009-10-30 2014-02-25 씨제이제일제당 (주) Ｄ-타가토스를 이용하여 제조되는 저칼로리 커피믹스 조성물
JP2013511963A (ja) * 2009-11-25 2013-04-11 ネステク ソシエテ アノニム 液体クリーマー及びそれらの製造方法
US20140010939A1 (en) 2011-02-08 2014-01-09 Nutrinova Nutrition Specialties & Food Ingredients Gmbh Sweetness Enhancers, Sweetener Compositions, Methods of Making the Same and Consumables Containing the Same
CN102961388A (zh) * 2011-08-30 2013-03-13 三和淀粉工业株式会社 促进glp-1的分泌并且抑制gip的分泌的药剂
CN103929977B (zh) 2011-09-15 2016-08-10 Cj第一制糖株式会社 含糖解抑制剂成分的预防和改善肥胖症的甜味剂组合物
EP2866585B1 (en) 2012-06-27 2018-06-06 Celanese Sales Germany GmbH Taste-masking compositions, sweetener compositions and consumable product compositions containing the same
KR20140061091A (ko) * 2012-11-13 2014-05-21 삼성정밀화학 주식회사 거품 음료 조성물 및 그의 제조방법
EP2970370B1 (en) * 2013-03-15 2019-12-04 The Coca-Cola Company Novel mogrosides, compositions and purification methods
US10039834B2 (en) * 2013-07-12 2018-08-07 The Coca-Cola Company Compositions and methods using rebaudioside X to provide sweetness enhancement
EP3045047B2 (en) * 2013-09-13 2024-11-06 Mitsubishi Chemical Corporation Emulsified composition and milk drink
KR101488844B1 (ko) 2013-11-29 2015-02-03 씨제이제일제당(주) 커피추출후 잔여물로부터 타가토스를 제조하는 방법
US20160263170A1 (en) * 2014-01-30 2016-09-15 NatGood IP, LLC Natural sweetener
KR20160025275A (ko) * 2014-08-27 2016-03-08 대상 주식회사 과당 흡수 억제용 조성물 및 과당 흡수 억제 방법
CN104739848A (zh) * 2015-04-07 2015-07-01 福州乾正药业有限公司 L-阿拉伯糖与塔格糖的组合物及其制备方法和药物应用

Also Published As

Publication number Publication date
EP3453262B1 (en) 2023-05-03
US11406680B2 (en) 2022-08-09
US20200360458A1 (en) 2020-11-19
EP3453262A1 (en) 2019-03-13
MY200199A (en) 2023-12-13
KR20170125298A (ko) 2017-11-14
WO2017192021A1 (ko) 2017-11-09
CN109152382A (zh) 2019-01-04
ES2946171T3 (es) 2023-07-13
EP3453262A4 (en) 2020-01-08
JP2019517786A (ja) 2019-06-27
DK3453262T3 (da) 2023-06-06
JP6849171B2 (ja) 2021-03-24
PL3453262T3 (pl) 2023-08-28

Similar Documents

Publication Publication Date Title
US20170129919A1 (en) Cyclic dipeptide-containing composition
US20210227866A1 (en) Dietary supplement compositions
US20040058050A1 (en) Herbal sweetening composition
JP5432123B2 (ja) カカオ抽出物の新規な使用
US20170114030A1 (en) Composition with high content of cyclic dipeptide
KR101686898B1 (ko) 여주 및 산수유를 이용한 당뇨 예방 및 개선용 식품 조성물
KR101790800B1 (ko) 조 카페인 복합체, 조 카페인 복합체를 사용하는 개선된 식품, 그것의 사용 방법
US11406680B2 (en) Health functional food for inhibiting rise of blood glucose containing coffee and tagatose
EP2592950B1 (en) Isomaltulose for use in enhancing mental performance
TW200939975A (en) Dietary compositions for promoting weight loss
KR101883096B1 (ko) 쿠퍼펩타이드를 포함하는 급성 폐 손상 또는 급성 호흡곤란 증후군 예방 또는 치료용 약학 조성물
KR101965376B1 (ko) 인삼 건조 제품
US20080220052A1 (en) Body weight gain inhibitor
CN100431553C (zh) 改善咽下障碍用组合物
US20250101233A1 (en) Stable natural colourant
JP2008247858A (ja) ダイエット用の経口摂取用組成物
US20220079967A1 (en) Composition for improving vascular endothelial function
US6521274B1 (en) Prepared royal jelly with caloric value
JP7420366B2 (ja) ルチンの分解が抑制されたダッタンソバふすまの製造方法、及びその利用
TW202106310A (zh) 用於促進ｇｌｐ－１分泌之組成物
JP2004000164A (ja) α−グルコシダーゼ阻害剤及び組成物
JP5943516B2 (ja) Ｄ−ソルボースを有効成分とする生体機能改善用甘味料
JP2008094797A (ja) 肥満抑制剤及び該肥満抑制剤を含む高脂肪含有飲食品
WO2022008414A1 (en) Composition
JP2014045714A (ja) アンジオテンシンｉ変換酵素阻害剤組成物含有飲食品

Legal Events

Date Code Title Description
AS Assignment

Owner name: CJ CHEILJEDANG CORPORATION, KOREA, REPUBLIC OF

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PARK, BYUNG GYU;LEE, YOUNG MI;KIM, SEONG BO;AND OTHERS;REEL/FRAME:047377/0574

Effective date: 20181022

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION